Angelini Pharma S.p.A. (A.C.R.A.F. S.p.A.)

Privately held: no public share price

Assets

(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Cenobamate(Xcopri)
Approved
Sodium channels + GABA-A receptorsSmall molecule
Epilepsy
Focal Onset Seizures
Approved
Dopamine D2/D3 receptor + 5-HT7 receptor · Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule
SchizophreniaBipolar Depression

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
January 2027 (2)
Cenobamate · XcopriPhase 2Epilepsies, Partial
Est. primary completion 2027-01-31 · NCT06590896 · CT.gov ↗
What to watch
Cenobamate · XcopriPhase 3Epilepsy, Generalized
Est. primary completion 2027-01-31 · NCT06579573 · CT.gov ↗
What to watch
2028 (1)
March 2028 (1)
Cenobamate · XcopriPhase 3Partial Epilepsy
Est. primary completion 2028-03-30 · NCT07594158 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

31 January 2027FDA action dateCenobamatePDUFA date set for cenobamate oral suspension
US, FDA · Source ↗

Recent

4 November 2026Filing submittedCenobamateSK Biopharmaceuticals submits sNDA for cenobamate in PGTC seizures and pediatric focal-onset seizures
US, FDA · SK Biopharmaceuticals · Source ↗
15 June 2026Filing acceptedCenobamateFDA accepts NDA for cenobamate oral suspension
US, FDA · Source ↗

Financial reports

No financial reports recorded.